2621. An alternative method of acute lung injury classification for use in observational studies.
作者: Chirag V Shah.;Paul N Lanken.;A Russell Localio.;Robert Gallop.;Scarlett Bellamy.;Shwu-Fan Ma.;Carlos Flores.;Jeremy M Kahn.;Barbara Finkel.;Barry D Fuchs.;Joe G N Garcia.;Jason D Christie.
来源: Chest. 2010年138卷5期1054-61页
In observational studies using acute lung injury (ALI) as an outcome, a spectrum of lung injury and difficult-to-interpret chest radiographs (CXRs) may hamper efforts to uncover risk factor associations. We assessed the impact of excluding patients with difficult-to-classify or equivocal ALI diagnosis on clinical and genetic risk factor associations for ALI after trauma.
2622. Airway count and emphysema assessed by chest CT imaging predicts clinical outcome in smokers.
作者: Alejandro A Diaz.;Clarissa Valim.;Tsuneo Yamashiro.;Raúl San José Estépar.;James C Ross.;Shin Matsuoka.;Brian Bartholmai.;Hiroto Hatabu.;Edwin K Silverman.;George R Washko.
来源: Chest. 2010年138卷4期880-7页
Recently, it has been shown that emphysematous destruction of the lung is associated with a decrease in the total number of terminal bronchioles. It is unknown whether a similar decrease is visible in the more proximal airways. We aimed to assess the relationships between proximal airway count, CT imaging measures of emphysema, and clinical prognostic factors in smokers, and to determine whether airway count predicts the BMI, airflow obstruction, dyspnea, and exercise capacity (BODE) index.
2623. Objective airway monitoring improves asthma control in the cold and flu season: a cluster randomized trial.
作者: Susan L Janson.;Kelly Wong McGrath.;Jack K Covington.;Robert B Baron.;Stephen C Lazarus.
来源: Chest. 2010年138卷5期1148-55页
The goals of asthma care are reductions in risk and impairment, but achieving these goals requires collaborative work between patients and their clinicians. The purpose of this study was to improve inhaled corticosteroid (ICS) adherence and asthma control by cueing therapeutic communication between patients with asthma and their primary care clinicians.
2624. Expression of the T helper 17-associated cytokines IL-17A and IL-17F in asthma and COPD.
作者: Camille Doe.;Mona Bafadhel.;Salman Siddiqui.;Dhananjay Desai.;Vijay Mistry.;Paul Rugman.;Margaret McCormick.;Joanne Woods.;Richard May.;Matthew A Sleeman.;Ian K Anderson.;Christopher E Brightling.
来源: Chest. 2010年138卷5期1140-7页
Asthma and COPD are characterized by airway dysfunction and inflammation. Neutrophilic airway inflammation is a common feature of COPD and is recognized in asthma, particularly in severe disease. The T helper (Th) 17 cytokines IL-17A and IL-17F have been implicated in the development of neutrophilic airway inflammation, but their expression in asthma and COPD is uncertain.
2625. Pulmonary hypertension in hemolytic disorders: pulmonary vascular disease: the global perspective.
The inherited hemoglobin disorders sickle cell disease and thalassemia are the most common monogenetic disorders worldwide. Pulmonary hypertension is one of the leading causes of morbidity and mortality in adult patients with sickle cell disease and thalassemia, and hemolytic disorders are potentially among the most common causes of pulmonary hypertension. The pathogenesis of pulmonary hypertension in hemolytic disorders is likely multifactorial, including hemolysis, impaired nitric oxide (NO) bioavailability, chronic hypoxemia, chronic thromboembolic disease, chronic liver disease, and asplenia. In contrast to patients with traditional forms of pulmonary arterial hypertension, patients with hemolytic disorders have a mild-to-moderate degree of elevation in mean pulmonary pressures, with mild elevations in pulmonary vascular resistance. The hemodynamic etiology of pulmonary hypertension in these patients is multifactorial and includes pulmonary arterial hypertension, pulmonary venous hypertension, and pulmonary hypertension secondary to a hyperdynamic state. Currently, there are limited data on the effects of any specific treatment modality for pulmonary hypertension in patients with hemolytic disorders. It is likely that maximization of treatment of the primary hemoglobinopathy in all patients and treatment with selective pulmonary vasodilators and antiproliferative agents in patients with pulmonary arterial hypertension would be beneficial. However, there is still a major need for large multinational trials of novel therapies for this patient population.
2626. Schistosomiasis-associated pulmonary hypertension: pulmonary vascular disease: the global perspective.
作者: Brian B Graham.;Angela Pontes Bandeira.;Nicholas W Morrell.;Ghazwan Butrous.;Rubin M Tuder.
来源: Chest. 2010年137卷6 Suppl期20S-29S页
Inflammation is likely a critical underlying etiology in many forms of severe pulmonary hypertension (PH), and schistosomiasis-associated PH, one of the most common causes of PH worldwide, is likely driven by the host response to parasite antigens. More than 200 million people are infected with schistosomiasis, the third most common parasitic disease, and approximately 1% of those chronically infected develop PH. Acute cutaneous infection causes inflammation at the site of parasite penetration followed by a subacute immune complex-mediated hypersensitivity response as the parasite migrates through the lungs. Chronic schistosomiasis infection induces a granulomatous inflammation around ova deposited in the tissue. In particular, Schistosoma mansoni migrates to the portal venous system and causes preportal fibrosis in a subset of individuals and appears to be a prerequisite for PH. Portal hypertension facilitates shunting of ova from the portal system to the pulmonary arterial tree, resulting in localized periovular pulmonary granulomas. The pulmonary vascular remodeling is likely a direct consequence of the host inflammatory response, and portopulmonary hypertension may be a significant contributor. New specific therapies available for PH have not been widely tested in patients with schistosomiasis and often are unavailable for those infected in resource-poor areas of the world where schistosomiasis is endemic. Furthermore, the current PH therapies in general target vasodilation rather than vascular remodeling and inflammation. Further research is needed into the pathogenic mechanism by which this parasitic infection results in pulmonary vascular remodeling and PH, which also may be informative regarding the etiology of other types of PH.
2627. Pulmonary hypertension associated with HIV infection: pulmonary vascular disease: the global perspective.
作者: Sharilyn Almodovar.;Stefania Cicalini.;Nicola Petrosillo.;Sonia C Flores.
来源: Chest. 2010年137卷6 Suppl期6S-12S页
The success of antiretroviral therapies in improving the survival of patients infected with HIV and reducing HIV-associated opportunistic infections is undisputed. Nevertheless, long-term outcomes such as noninfectious cardiovascular complications, including cardiomegaly, pericarditis, myocarditis, and pulmonary arterial hypertension, are now serious concerns. The lung is a frequent target organ for disorders associated with HIV infection. HIV-related pulmonary arterial hypertension (HRPAH) affects more individuals who are infected with HIV than individuals who are uninfected. Moreover, the long-standing estimated prevalence of HRPAH in developed countries (calculated at 0.5%) is increasing as more clinician-scientists unify their efforts to screen patients who are pulmonary asymptomatic for pulmonary arterial hypertension. In order to decrease mortality, efforts are directed at early detection, diagnosis, and therapeutic interventions before the disease compromises patients' quality of life. This article reviews the logistics of screening approaches for HRPAH and discusses the substantial disease burden currently faced by developing countries, where the prevalence of HIV infection is higher and complicated by hyperendemic risk factors, limited access to antiretrovirals, and lack of screening tools. We also present mechanistic insights into HRPAH, including the role of HIV proteins and their potential use as screening tools, and, finally, areas that still need intense research.
2628. Surgical correction of gastroesophageal reflux in lung transplant patients is associated with decreased effector CD8 cells in lung lavages: a case series.
作者: David C Neujahr.;Aminu Mohammed.;Onome Ulukpo.;Seth D Force.;Allan M Ramirez.;Andres Pelaez.;E Clinton Lawrence.;Christian P Larsen.;Allan D Kirk.
来源: Chest. 2010年138卷4期937-43页
Lung transplantation is associated with a high incidence of gastroesophageal reflux disease (GERD). The presence of GERD is considered a risk factor for the subsequent development of obliterative bronchiolitis (OB), and surgical correction of GERD by gastric fundoplication (GF) may be associated with increased freedom from OB. The mechanisms underlying a protective effect from OB remain elusive. The objective of this study was to analyze the flow cytometric properties of BAL cells in patients who have undergone GF early after transplant.
2629. Clinical characteristics and outcomes of sepsis-related vs non-sepsis-related ARDS.
作者: Chau-Chyun Sheu.;Michelle N Gong.;Rihong Zhai.;Feng Chen.;Ednan K Bajwa.;Peter F Clardy.;Diana C Gallagher.;B Taylor Thompson.;David C Christiani.
来源: Chest. 2010年138卷3期559-67页
ARDS may occur after either septic or nonseptic injuries. Sepsis is the major cause of ARDS, but little is known about the differences between sepsis-related and non-sepsis-related ARDS.
2630. Long-term survival outcomes by smoking status in surgical and nonsurgical patients with non-small cell lung cancer: comparing never smokers and current smokers.
作者: Robert A Meguid.;Craig M Hooker.;James Harris.;Li Xu.;William H Westra.;J Timothy Sherwood.;Marc Sussman.;Stephen M Cattaneo.;James Shin.;Solange Cox.;Joani Christensen.;Yelena Prints.;Nance Yuan.;Jennifer Zhang.;Stephen C Yang.;Malcolm V Brock.
来源: Chest. 2010年138卷3期500-9页
Survival outcomes of never smokers with non-small cell lung cancer (NSCLC) who undergo surgery are poorly characterized. This investigation compared surgical outcomes of never and current smokers with NSCLC.
2631. Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype.
作者: Lorinda Chung.;Juliana Liu.;Lori Parsons.;Paul M Hassoun.;Michael McGoon.;David B Badesch.;Dave P Miller.;Mark R Nicolls.;Roham T Zamanian.
来源: Chest. 2010年138卷6期1383-94页
REVEAL (the Registry to Evaluate Early and Long-term Pulmonary Arterial Hypertension Disease Management) is the largest US cohort of patients with pulmonary arterial hypertension (PAH) confirmed by right-sided heart catheterization (RHC), providing a more comprehensive subgroup characterization than previously possible. We used REVEAL to analyze the clinical features of patients with connective tissue disease-associated PAH (CTD-APAH).
2632. Clinical course of avian influenza A(H5N1) in patients at the Persahabatan Hospital, Jakarta, Indonesia, 2005-2008.
作者: Priyanti Z Soepandi.;Erlina Burhan.;Hadiarto Mangunnegoro.;Arifin Nawas.;Tjandra Yoga Aditama.;Lia Partakusuma.;Fathiyah Isbaniah.;Mukhtar Ikhsan.;Boedi Swidarmoko.;Agung Sutiyoso.;Suhud Malik.;Rachel Benamore.;J Kevin Baird.;Walter R J Taylor.
来源: Chest. 2010年138卷3期665-73页
Limited understanding of the presentation and course of influenza A(H5N1) infection in humans hinders evidence-based management.
2633. Predictors of influenza vaccination in the Cystic Fibrosis Foundation patient registry, 2006 through 2007.
作者: Justin R Ortiz.;Kathleen M Neuzil.;John C Victor.;Moira L Aitken.;Christopher H Goss.
来源: Chest. 2010年138卷6期1448-55页
Influenza vaccination is recommended for all persons with cystic fibrosis (CF). Despite this recommendation, no study has been performed to determine factors associated with receipt of influenza vaccination among persons with CF.
2634. Association of obstructive sleep apnea risk with asthma control in adults.
作者: Mihaela Teodorescu.;David A Polomis.;Stephanie V Hall.;Mihai C Teodorescu.;Ronald E Gangnon.;Andrea G Peterson.;Ailiang Xie.;Christine A Sorkness.;Nizar N Jarjour.
来源: Chest. 2010年138卷3期543-50页
Unrecognized obstructive sleep apnea (OSA) may lead to poor asthma control despite optimal therapy. Our objective was to evaluate the relationship between OSA risk and asthma control in adults.
2635. An international randomized multicenter comparison of nasal potential difference techniques.
作者: George M Solomon.;Michael W Konstan.;Michael Wilschanski.;Joanne Billings.;Isabelle Sermet-Gaudelus.;Frank Accurso.;François Vermeulen.;Elina Levin.;Heather Hathorne.;Ginger Reeves.;Gina Sabbatini.;Aubrey Hill.;Nicole Mayer-Hamblett.;Melissa Ashlock.;John Paul Clancy.;Steven M Rowe.
来源: Chest. 2010年138卷4期919-28页
The transepithelial nasal potential difference (NPD) is used to assess cystic fibrosis transmembrane conductance regulator (CFTR) activity. Unreliability, excessive artifacts, and lack of standardization of current testing systems can compromise its use as a diagnostic test and outcome measure for clinical trials.
2636. Risk factors and predictive clinical scores for asthma exacerbations in childhood.
作者: Erick Forno.;Anne Fuhlbrigge.;Manuel E Soto-Quirós.;Lydiana Avila.;Benjamin A Raby.;John Brehm.;Jody M Sylvia.;Scott T Weiss.;Juan C Celedón.
来源: Chest. 2010年138卷5期1156-65页
Asthma is a major public health problem that affects millions of children worldwide, and exacerbations account for most of its morbidity and costs. Primary-care providers lack efficient tools to identify children at high risk for exacerbations. We aimed to construct a clinical score to help providers to identify such children.
2637. Upper-respiratory viral infection, biomarkers, and COPD exacerbations.
作者: Omar Kherad.;Laurent Kaiser.;Pierre-Olivier Bridevaux.;François Sarasin.;Yves Thomas.;Jean-Paul Janssens.;Olivier T Rutschmann.
来源: Chest. 2010年138卷4期896-904页
Respiratory viruses frequently are recovered in the upper-respiratory tract during acute exacerbations of COPD (AECOPD), but their role as contributing pathogens remains unclear. The usefulness of procalcitonin and C-reactive protein as indicators of the presence or absence of viral infection in this setting also needs to be evaluated.
2638. The association between BMI and plasma cytokine levels in patients with acute lung injury.
作者: Renee D Stapleton.;Anne E Dixon.;Polly E Parsons.;Lorraine B Ware.;Benjamin T Suratt.; .
来源: Chest. 2010年138卷3期568-77页
Obesity is associated with poor outcomes in many diseases, although recent data suggest that acute lung injury (ALI) is an exception. This is particularly interesting because obesity is marked by increased levels of proinflammatory mediators associated with increased morbidity and mortality in ALI. We hypothesized that cytokine response might be attenuated in patients who are obese and critically ill or that obesity might modify the relationship between plasma cytokines and clinical outcomes in ALI.
2639. Trends and burden of bronchiectasis-associated hospitalizations in the United States, 1993-2006.
作者: Amy E Seitz.;Kenneth N Olivier.;Claudia A Steiner.;Ruben Montes de Oca.;Steven M Holland.;D Rebecca Prevots.
来源: Chest. 2010年138卷4期944-9页
Current data on bronchiectasis prevalence, trends, and risk factors are lacking; such data are needed to estimate the burden of disease and for improved medical care and public health resource allocation. The objective of the present study was to estimate the trends and burden of bronchiectasis-associated hospitalizations in the United States.
2640. Reflux-induced collagen type v sensitization: potential mediator of bronchiolitis obliterans syndrome.
作者: Joseph L Bobadilla.;Ewa Jankowska-Gan.;Qingyong Xu.;Lynn D Haynes.;Alejandro Munoz del Rio.;Keith Meyer.;Daniel S Greenspan.;Nilto De Oliveira.;William J Burlingham.;James D Maloney.
来源: Chest. 2010年138卷2期363-70页
Lung transplantation continues to have poor long-term survival partly because of the high incidence of bronchiolitis obliterans syndrome (BOS). Gastroesophageal reflux disease (GERD) has been implicated in BOS pathogenesis. We investigated the role of collagen type V [col(V)] sensitization in this process.
|